Greetings from MyCancerHaven!
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Panelists Discuss Who Shouldn’t Receive Quadruplet CD38 Regimens in NDMM.
Dr. Landgren on Recent Shifts in the Treatment Paradigm for Multiple Myeloma
Optimal Bridging Therapy Strategies for CAR T Treatment in Early R/R MM.
Managing Relapsed/Refractory Multiple Myeloma: Current Approaches and Future Directions in Community
Clinical Perspectives: Identifying Patients Unsuitable for Quadruplet CD38 Regimens in NDMM.
Expert Perspectives: Comparing and Navigating Findings from CEPHEUS and IMROZ Studies.
Dr. Lin Discusses Cilta-Cel for Lenalidomide-Refractory Multiple Myeloma Treatment.
Cilta-Cel in Early Relapsed Myeloma: Emerging CARTITUDE-4 CAR T Data.
Dr. Phull Compares Real-World and Trial Data for CAR T in R/R MM.
Dr. Bishop Discusses Anito-Cel's Potential Impact on Multiple Myeloma Treatment.
Exploring Post-Autologous Transplant Maintenance Strategies in Multiple Myeloma Treatment.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Panelists Discuss Who Shouldn’t Receive Quadruplet CD38 Regimens in NDMM.
Dr. Landgren on Recent Shifts in the Treatment Paradigm for Multiple Myeloma
Optimal Bridging Therapy Strategies for CAR T Treatment in Early R/R MM.
Managing Relapsed/Refractory Multiple Myeloma: Current Approaches and Future Directions in Community
Clinical Perspectives: Identifying Patients Unsuitable for Quadruplet CD38 Regimens in NDMM.
Expert Perspectives: Comparing and Navigating Findings from CEPHEUS and IMROZ Studies.
Dr. Lin Discusses Cilta-Cel for Lenalidomide-Refractory Multiple Myeloma Treatment.
Cilta-Cel in Early Relapsed Myeloma: Emerging CARTITUDE-4 CAR T Data.
Dr. Phull Compares Real-World and Trial Data for CAR T in R/R MM.
Dr. Bishop Discusses Anito-Cel's Potential Impact on Multiple Myeloma Treatment.
Exploring Post-Autologous Transplant Maintenance Strategies in Multiple Myeloma Treatment.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
